Author Archives: admin

  • -

TENS PEMF therapy in the management of Cancer

The following studies represent some of the clinical evidence for the use of TENS PEMF therapy in the management of Cancer.

PEMF therapy for drug resistant cancer

Please note that these studies were not done on the Rife PEMF device, but rather represent studies including outputs which can be found on the various Rife Model MA devices.

ELF Magnetic field induce tumor growth inhibition and apoptosis Significant tumor growth inhibition – up to 50%. No effect on normal healthy cells. ELF at 50Hz for four weeks.
Growth of injected melanoma cells is suppressed by whole body exposure to specific spatial-temporal configurations of weak intensity magnetic fields Mice exposed to the field that was rotated through the three spatial dimensions and through all three planes every 2 sec did not grow tumors after 38 days. However, the mice in the sham-field and reference controls showed massive tumors after 38 days. Tumor growth was also affected by the intensity of the field, with mice exposed to a weak intensity field (1-5 nT) forming smaller tumors than mice exposed to sham or stronger, high intensity (2-5 microT) fields.
Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields Treatment with intrabuccally administered amplitude-modulated electromagnetic fields is safe, well tolerated, and shows

evidence of antitumor effects in patients with advanced HCC.

410 – 642Hz very low AM ELF
Low Intensity and Frequency Pulsed Electromagnetic

Fields Selectively Impair Breast Cancer Cell Viability

We observed a discrete window of vulnerability of MCF7 cells to PEMFs of 20 Hz frequency, 3 mT magnitude and

exposure duration of 60 minutes per day. The cell damage accrued in response to PEMFs increased with time and gained

significance after three days of consecutive daily exposure. By contrast, the PEMFs parameters determined to be most

cytotoxic to breast cancer MCF-7 cells were not damaging to normal MCF-10 cells.

20Hz 3mT daily for 60 minutes a day
Mechanisms and therapeutic effectiveness of pulsed

electromagnetic field therapy in oncology

 In vitro studies support antineoplastic and antiangiogenic

effects of PEMF therapy. Several mechanisms of PEMF

therapy have been elucidated. For example, PEMFs inhibit

cancer growth by disrupting the mitotic spindle in a process

mediated by interference of spindle tubulin orientation

and induction of dielectrophoresis. Furthermore, PEMF

therapy modulates gene expression and protein synthesis interacting with specific DNA sequences within gene promoter

regions [18, 38, 40, 41, 58, 103]. In addition, PEMFs

inhibit angiogenesis in tumor tissues, suppressing tumor

vascularization and reducing tumor growth, as shown by

in vivo studies [95-99, 104].

The specific claim, supported by the described in vivo

studies, is that all treated groups showed slower tumor

growth rate if compared with untreated control group,

confirming that PEMF therapy can modulate the physiology

and electrochemistry of cancer cells and influence

cell membrane systems and mitosis. In addition, PEMFs

induce some changes in membrane transport capacity

through impacting the osmotic potential, ionic valves and

leading to reduction in cellular stress factors, increase in

the rate of DNA transcription, and modulation of immune

response [105].

PEMFs have also an immunomodulatory effect, as supported

by in vivo evidence showing an increase in tumor

necrosis factor alpha levels that induce an anti-tumoral

response, leading to the activation of a proapoptotic pathway

induced by caspase-8 interaction with Fas-associated

death domain, in the spleen of the murine melanoma

mouse model after a 16-day therapy [78]. Changes in

blood pressure, skin electrical resistance, and pulse amplitude

in 163 oncology patients exposed to tumor-specific

PEMF frequencies have also been reported suggesting that

PEMF therapy does not only target neoplastic cells, but

may also have systemic effects [15]. However, long-term

PEMF treatment in HCC patients is not toxic, confirming

the safety of PEMF therapy that employs 100,000 times

lower frequencies if compared with radiofrequency ablation

that is also employed for treatment of HCC [55].

In conclusion, two clinical studies have used

PEMF therapy for cancer treatment. These studies show

that PEMF therapy is safe and promising compared to

other available cancer therapies. In the future, PEMFs

could be used not only as primary therapy but also in

combination with other common antineoplastic therapies.

Given that new portable and affordable PEMF devices

are increasingly available on the market, future controlled

clinical studies are expected to further determine the

potential of PEMF therapy in oncology

PMF sensitized fibrosarcoma and hepatocellular carcinoma to mitomycin C An article published in the Japanese Journal of Cancer research, investigated the effects of PMF therapy in combination with mitomycin C for the treatment of fibrosarcoma and hepatocellular carcinoma.[1]

WKA rats were exposed to a frequency of 200Hz immediately after IV injections of mitomycin C. The survival rates of the rats were recorded. Cultured cells were also used to study the efficacy of PMF and mitomycin C, and a combination of the two.

Survival rates of the untreated rats were 0% in the non-treated group, 34% in the group treated with mitomycin C only, and 47% for the PMF only group. For the group who received a combination of PMF and mitocycin C, the survival rate was 77%. The combination increased lifespan of the PMF mitomycin C group which was significantly prolonged at 17,6%. The efficiencies of the cells in the cultures of both cell lines were also significantly suppressed in the combination therapy group when compared with those in the other single therapy groups.

This study clearly indicates the possibility that PEMF therapy could improve and enhance the efficacy of drugs like mitomycin C.

200Hz
Low frequency EMF sensitizes cisplatin-resistant ovarian adenocarcinoma

 

Platinum based drugs like cisplatin often form the first line of therapy for cancers including testicular, bladder, esophageal cancer, lung cancer, mesothelioma, brain tumors, neuroblastoma ovarian and colorectal tumors but the use of cisplatin also often results in chemotherapy resistant cancers.[2]

In the search for a way to re-sensitize cancers to cisplatin, researchers investigated the use of extra-low frequency electromagnetic field therapy on cisplatin-resistant A2780 ovarian cancer cells. Cells were exposed to 200hz at 50 Gauss.

Researchers found that EL-EMF decreased proliferation of the cells independently of cisplatin. They also saw a decreased proliferation rate of 40 % in the cisplatin only group but the cells treated with a combination of cisplatin and EL-EMF showed a 71 % decrease in viability in rats.[3] They also saw a large increase in late apoptosis in the combination group as indicated in the graph below:

Histogram from percentage of live and dead cells from AO/PI staining for A2780 cells, data are presented as means (±SD)

The study concluded that EL-EMF therapy at 200Hz can help to sensitize cancer cells to cisplatin and improved the efficacy of cisplatin.

 

200Hz
Pulsed magnetic fields enhance the potency of daunorubicin in human carcinoma cell lines

 

Researchers studied the effects of PMF pulses of 250Hz on multidrug resistant human carcinoma cells. They inoculated mice with a multidrug resistant form of human carcinoma. They then treated the resultant tumors with pulsed magnetic therapy only or a combination of PMF therapy and daunorubicin.

Researchers found that amongst the various groups, significant differences in the tumor volume were found between PMF + saline and PMF + daunorubicin groups at 39 days and 42 days. No mice died in the PMF alone group, and no toxicity attributable to PMF was found during the experimental period.

The results indicated that the efficacy of daunorubicin was potentiated in vitro by PMF exposure when PMF exposure occurred in the presence of the drug.

250Hz
PEMF improves the effects of doxorubicin in Osteosarcoma

 

In another study, researchers studied the potential drug resistance modification effects of PEMF stimulation in multidrug resistant mouse osteosarcoma. PEMF stimulation reversed doxorubicin resistance. The concluded that PEMFs reversed the doxorubicin resistance of the MOS/ADR1 cells by inhibiting P-gp function. The results suggested that PEMFs may be useful as a local treatment for multidrug resistant osteosarcoma
50Hz enhances the antiproliferative effects of 5-fluorouracil in breast cancer

 

Finally, researchers explored the effects of pre-exposure to 50Hz to help to reduce resistance to 5-fluorouracil to enhance efficacy of the drug. The study explored the combined effect of 50 Hz-EMFs and 5-FU in the treatment of breast cancer.

Researchers found that pre-exposure to 50 Hz-EMFs enhanced the antiproliferative effect of 5-FU in breast cancer cell line MCF-7 in a dose-dependent manner but did not affect normal human breast epithelial cell lines.

They concluded that the enhanced cytotoxic activity of 5-FU on MCF7 cells through promoting entry into the S phase of the cell cycle via exposure to 50 Hz-EMFs, may provide a novel method of cancer treatment based on the combinatorial use of 50 Hz-EMFs and chemotherapy.

50Hz

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918102/

[2] https://www.ncbi.nlm.nih.gov/pubmed/21892204

[3] https://www.ncbi.nlm.nih.gov/pubmed/26370097

For more information on cancer and drug resistance please read

The Rife PEMF Model MA200 Cancer Protocol

PEMF therapy for drug resistant cancer

PEMF in cancer therapy – PEMF could be a promising modality

For more information, research and studies on TENS PEMF therapy in the management of Cancer, please join our newsletter or check back regularly for updates.

 


  • -

TENS PEMF therapy in the management of Drug Resistance Bacteria

The following studies represent some of the clinical evidence for the use of TENS PEMF therapy in the management of Drug Resistance Bacteria.

PEMF therapy for drug resistant cancer

Please note that these studies were not done on the Rife PEMF device, but rather represent studies including outputs which can be found on the various Rife Model MA devices.

For more information on TENS PEMF therapy in the management of Drug Resistance Bacteria please read: PEMF therapy for Drug Resistant Conditions or PEMF therapy for drug resistant cancer

Electromagnetic augmentation of antibiotic efficacy in infection of orthopaedic implants. Infection of orthopaedic implants is a significant problem, with increased antibiotic resistance of adherent 'biofilm' bacteria causing difficulties in treatment. We have investigated the in vitro effect of a pulsed electromagnetic field (PEMF) on the efficacy of antibiotics in the treatment of infection of implants. Five-day biofilms of Staphylococcus epidermidis were grown on the tips of stainless-steel pegs. They were exposed for 12 hours to varying concentrations of gentamicin or vancomycin in microtitre trays at 37 degrees C and 5% CO2. The test group were exposed to a PEMF. The control tray was not exposed to a PEMF. After exposure to antibiotic the pegs were incubated overnight, before standard plating onto blood agar for colony counting. Exposure to a PEMF increased the effectiveness of gentamicin against the five-day biofilms of Staphylococcus epidermidis. In three of five experiments there was reduction of at least 50% in the minimum biofilm inhibitory concentration. In a fourth experiment there was a two-log difference in colony count at 160 mg/l of gentamicin. Analysis of variance (ANOVA) confirmed an effect by a PEMF on the efficacy of gentamicin which was significant at p < 0.05. There was no significant effect with vancomycin.
Augmentation of antibiotic activity by low-frequency electric and electromagnetic fields examining Staphylococcus aureus in broth media. Systemic treatment of biomaterial-associated bacterial infections with high doses of antibiotics is an established therapeutic concept. The purpose of this in vitro study was to determine the influence of magnetic, electromagnetic, and electric fields on gentamicin-based, antibiotic therapy. It has been previously reported that these fields are successful in the treatment of bone healing and reducing osteitis in infected tibia-pseudarthroses. Four separate experimental setups were used to expose bacterial cultures of Staphylococcus aureus both in Mueller-Hinton broth (MHB) and on Mueller-Hinton agar (MHA), in the presence of gentamicin, to (1) a low-frequency magnetic field (MF) 20 Hz, 5 mT; (2) a low-frequency MF combined with an additional alternating electric field (MF + EF) 20 Hz, 5 mT, 470 mV/cm; (3) a sinusoidal alternating electric field (EF AC) 20 Hz, 470 mV/cm; and (4) a direct current electric field (EF DC) 588 mV/cm. No significant difference between samples and controls was detected on MHA. However, in MHB each of the four fields applied showed a significant growth reduction of planktonically grown Staphylococcus aureus in the presence of gentamicin between 32% and 91% within 24 h of the experiment. The best results were obtained by a direct current EF, decreasing colony-forming units (CFU)/ml more than 91%. The application of electromagnetic fields in the area of implant and bone infections could offer new perspectives in antibiotic treatment and antimicrobial chemotherapy.
Drug resistance modification using pulsing electromagnetic field stimulation for multidrug resistant mouse osteosarcoma cell line. Multidrug resistance (MDR) is one of the major problems in osteosarcoma chemotherapy. Therefore, methods of overcoming MDR are urgently needed. In this study, we investigated the effects of pulsing electromagnetic field stimulation (PEMFs) on a MDR murine osteosarcoma cell line which strongly expresses P-glycoprotein (P-gp). To assess the reversal effects of PEMFs on doxorubicin (DOX) resistance, MTT assay was applied. Viable cells were assessed by the trypan blue exclusion test. Fluorescence intensity of DOX binding to nuclear DNA of each cell was measured using a cytofluorometer. Changes in P-gp expression in each cell were detected by the indirect immunofluorescence method using an antibody to Pgp. PEMFs increased DOX binding ability to nuclear DNA and inhibited cell growth, although it had no significant effect on P-gp expression. These findings indicated that PEMFs reversed the DOX resistance of the MOS/ADR1 cells by inhibiting P-gp function. The results suggested that PEMFs may be useful as a local treatment for MDR osteosarcoma.

For more information, research and studies on TENS PEMF therapy in the management of Drug Resistance Bacteria, please join our newsletter or check back regularly for updates.


  • -

TENS PEMF therapy and Bacteria

The following studies represent some of the clinical evidence for the use of TENS PEMF therapy and Bacteria. Please note that these studies were not done on the Rife PEMF device, but rather represent studies including outputs which can be found on the various Rife Model MA devices.

For more information on TENS PEMF and bacteria, read PEMF therapy for Drug Resistant Conditions

TENS PEMF for Fatigue

Effects of 50 Hz Magnetic Fields on the Viability of Different Bacterial Strains The effect of a 50 Hz magnetic field on the growth of different bacterial strains was studied. We used bacteria with different cell shapes. We compared rod-shaped bacteria (E. coli, L. adecarboxylata) and spherical bacteria (S. aureus, P. denitrificans, S. paucimobilis, R. erythropolis). The growth curves of control and magnetic fields exposed samples were measured. The cylindrical coil induced magnetic fields with inductions up to 10 mT. Duration of exposure varied up to 24 min. Exposure took place at laboratory temperature (24–26°C) and the air ventilator maintained the temperature of sample. We observed the decrease of optical densities in exposed samples. The magnetic field effect was bigger for rod-like bacteria. 50Hz
Effect of extremely low frequency electromagnetic fields on bacterial membrane ELF-EMF caused changes in physicochemical properties of both Gram-positive and Gram-negative bacteria. Hyperpolarization was seen in S. aureus and EDTA-treated E. coli. Surface potential showed a positive shift in S. aureus contrariwise to the negative shift seen in EDTA-untreated E. coli. Respiratory activity increased in both bacteria. A slight decrease in growth was observed.  
The effects of different intensities, frequencies and exposure times of extremely low-frequency electromagnetic fields on the growth of Staphylococcus aureus and Escherichia coli Magnetic intensity, frequency and exposure time of ELF-EMFs changed the characteristic responses for both microorganisms. Samples exposed to ELF-EMF showed a statistically significant decrease compared to their controls in colony forming capability, especially at long exposure times. An exposure to 4 mT–20 Hz ELF-EMF of 6 h produced maximum inhibition of CFU compared to their controls for both microorganisms (95.2% for S. aureus and 85% for E. coli).  
Effects of low-frequency magnetic fields on bacteria Escherichia coli We observed analogous effects in both experimental conditions. The growth curve of the exposed bacteria was lower than the control one. The ability of bacteria to form colonies decreased with increasing magnetic field intensity and with increasing time of exposure. The decrease in oxidoreductive activity with increasing time of exposure was observed, but the effect was due to a lower amount of bacteria surviving the exposure to the magnetic fields. The decrease in oxidoreductive activity and ability to form colonies were compared with the assumption that the effect of magnetic field is probably bactericidal.  
Effects of extremely low-frequency electromagnetic fields on Helicobacter pylori biofilm.

 

The aim of this work was to investigate the effects of exposure to extremely low-frequency electromagnetic fields (ELF-EMF) both on biofilm formation and on mature biofilm of Helicobacter pylori. Bacterial cultures and 2-day-old biofilm of H. pylori ATCC 43629 were exposed to ELF-EMF (50 Hz frequency-1 mT intensity) for 2 days to assess their effect on the cell adhesion and on the mature biofilm detachment, respectively. All the exposed cultures and the respective sham exposed controls were studied for: the cell viability status, the cell morphological analysis, the biofilm mass measurement, the genotypic profile, and the luxS and amiA gene expression. The ELF-EMF acted on the bacterial population during the biofilm formation displaying significant differences in cell viability, as well as, in morphotypes measured by the prevalence of spiral forms (58.41%) in respect to the controls (33.14%), whereas, on mature biofilm, no significant differences were found when compared to the controls. The measurement of biofilm cell mass was significantly reduced in exposed cultures in both examined experimental conditions. No changes in DNA patterns were recorded, whereas a modulation in amiA gene expression was detected. An exposure to ELF-EMF of H. pylori biofilm induces phenotypic changes on adhering bacteria and decreases the cell adhesion unbalancing the bacterial population therefore reducing the H. pylori capability to protect itself.  

For more information, research and studies on TENS PEMF therapy and Bacteria, please join our newsletter or check back regularly for updates.


  • -

TENS PEMF therapy in the management of Back Pain

The following studies represent some of the clinical evidence for the use of TENS PEMF therapy in the management of Back Pain.

Please note that these studies were not done on the Rife PEMF device, but rather represent studies including outputs which can be found on the various Rife Model MA devices.

Decreased Opioid Utilization and Cost at One Year in Chronic Low Back Pain Patients Treated with Transcutaneous Electric Nerve Stimulation (TENS). Significantly fewer patients in the TENS group required opioids at final follow-up (57.7 vs. 60.3%). TENS patients also had significantly fewer annual per-patient opioid costs compared to non-TENS patients ($169 vs. $192). There were significantly lower event rates in TENS patients compared to non-TENS patients when measured by opioid utilization (characterized by frequency of prescription refills) (3.82 vs. 4.08, respectively) or pharmacy utilization (31.67 vs. 32.25). The TENS group also demonstrated a significantly lower cost of these utilization events ($44 vs. $49) and avoided more opioid events (20.4 events fewer per 100 patients annually). Various TENS devices used
Direct and Indirect Benefits Reported by Users of Transcutaneous Electrical Nerve Stimulation for Chronic Musculoskeletal Pain: Qualitative Exploration Using Patient Interviews. Data analysis indicated that distraction from pain and a reduction in the sensations associated with muscle tension or spasm should be considered as separate outcomes from pain relief. These direct benefits led to a wide range of indirect benefits dependent on patient decision making, including medication reduction, enhanced function, psychological benefits, and enhanced ability to rest. Various TENS
[Comparison of the analgesic effect of interferential current (IFC) and TENS in patients with low back pain]. After 2-weeks therapy there was improvement in the VAS and Laitinen scale (all components) in both groups, except for the part of the Laitinen scale on the reduction of activity in the group II (TENS). There was no statistically significant difference between the TENS and IF groups in reducing the intensity and other aspects of pain (frequency, pain medication and activity limitation) under the influence of therapy (p > 0.05). Interferential current and TENS therapy are effective for pain relief in patients with low back pain. The study showed equal analgesic efficacy of both treatments.  
Efficacy of pulsed electromagnetic therapy for chronic lower back pain: a randomized, double-blind, placebo-controlled study. Active PEMT (n = 17) or placebo treatment (n = 19) was performed three times a week for 3 weeks. Patients were assessed using a numerical rating scale (NRS) and revised Oswestry disability scores for 4 weeks after therapy. PEMT produced significant pain reduction throughout the observation period compared with baseline values. The percentage change in the NRS score from baseline was significantly greater in the PEMT group than the placebo group at all three time-points measured. The mean revised Oswestry disability percentage after 4 weeks was significantly improved from the baseline value in the PEMT group, whereas there were no significant differences in the placebo group. In conclusion, PEMT reduced pain and disability and appears to be a potentially useful therapeutic tool for the conservative management of chronic lower back pain.  
A Meta-Analysis of Transcutaneous Electrical Nerve Stimulation for Chronic Low Back Pain. Included were nine level I and four level II studies, encompassing 267 patients (39% male) who had a mean follow-up of seven weeks (range; 2 to 24 weeks). The mean duration of treatment was six weeks (range; 2 to 24 weeks). The standardized mean difference in pain from pre- to post-treatment for TENS was 0.844, which demonstrated significant improvement of TENS on pain reduction. Treatment of chronic low back pain with TENS demonstrated significant pain reduction. The application of TENS may lead to less pain medication usage and should be incorporated into the treatment armamentarium for chronic low back pain.  
An open-label pilot study of pulsed electromagnetic field therapy in the treatment of failed back surgery syndrome pain Relative to baseline, responders reported an average 44% and 55% reduction in back PI and leg PI (respectively), and an average 13% improvement in Oswestry Disability Index scores. In the per-protocol population, 50% of responders and 12% of nonresponders reported less analgesia consumption at the end of treatment versus baseline. Sixty-seven percent of per-protocol responders and 0% of nonresponders reported clinically meaningful improvement in overall well-being on the Patient Global Impression of Change scale  

 

Download our back pain protocol here: PEMF for Lower Back Pain – Protocol

For more information, research and studies on TENS PEMF therapy in the management of Back Pain, please join our newsletter or check back regularly for updates.


  • -

TENS PEMF therapy in the management of Autism Spectrum Disorder

The following studies represent the clinical evidence for the use of TENS PEMF therapy in the management of Autism Spectrum Disorder. Please note these studies were not done on the Rife PEMF device, but do represent outputs available on our devices.

PEMF for Boosting the Immune System

rTMS neuromodulation improves electrocortical functional measures of information processing and behavioral responses in autism Post-TMS evaluations showed decreased irritability and hyperactivity on the Aberrant Behavior Checklist (ABC), and decreased stereotypic behaviors on the Repetitive

Behavior Scale (RBS-R). Results from our study indicate that rTMS improves executive functioning in ASD as evidenced by normalization of ERP responses and behavioral reactions (RT,

accuracy) during executive function test, and also by improvements in clinical evaluations.

18 sessions of 1 Hz rTMS applied over the dorso-lateral prefrontal cortex
A double-blind, randomized trial of deep repetitive transcranial magnetic stimulation (rTMS) for autism spectrum disorder. Participants in the active condition showed a near significant reduction in self-reported social relating symptoms from pre-treatment to one-month follow-up, and a significant reduction in social relating symptoms (relative to sham participants) for both post-treatment assessments. Those in the active condition also showed a reduction in self-oriented anxiety during difficult and emotional social situations from pre-treatment to one-month follow-up. There were no changes for those in the sham condition. 5 Hz, 10-s train duration, 20-s inter-train interval) for 15 min (1500 pulses per session)
Effect of Anodal Transcranial Direct Current Stimulation on

Autism: A Randomized Double-Blind Crossover Trial

The CARS revealed a statistically significant amelioration of total score (𝑃 <0.001; Table 2). After 7 days of anodal tDCS, the tDCS group shifted from 34.95 to32.2. There was statistical change in total ATEC score observed in the active compared to sham group

(𝐹(1,39) = 23.143; 𝑃 < 0.001), as well as in health and

behavioral problem (𝐹(1,39) = 4.815; 𝑃 = 0.034), sociability

(𝐹(1,39) = 6.525; 𝑃 = 0.015), and sensory/cognitive awareness

(𝐹(1,39) = 6.171; 𝑃 = 0.018). The between group

CGAS showed statistical increase in the active compared

to sham group at 7 days after treatment (𝑃 = 0.042).

Eighteen of 20 children (90%) in the active tDCS group

demonstrated an increase in the score (from mean score

54.35 ± 11.07 at baseline to 60.00 ± 10.57 at the end of

treatment), whereas 1 of 20 children (5%) in the sham group

showed an improvement. Among those who received active tDCS, only 2 children were reported to be “minimally worse,” whereas the rest were rated as “much improved” (9 of 20) and “minimally improved” (8 of 20). This gave a response rate of 85% for active tDCS. In the sham group, 3 children were rated as

“much improved” to some extent, whereas 4 children were

reported to have “minimally improved.” Interestingly, 7 children in the sham group were rated as “worsened” after

treatment. Although the mechanisms of action of tDCS and rTMS

are not fully understood, both techniques appear to produce

similar changes in the activity of neuronal cell and thus

may lead to similar clinical outcomes

5 consecutive days of 1mA anodal or sham tDCS stimulation

(depending on order assignment) for 20 min;

Transcranial direct current stimulation for hyperactivity and noncompliance in autistic disorder. Eight out of 10 study completers improved in their abnormal behaviors, reaching an average reduction of 26.7% of the total ABC score. The remaining two patients showed no changes. In the whole group of completers, among the five subscales contributing to the significant reduction of the total score, the most remarkable and statistically significant change was seen in the subscale assessing hyperactivity and non-compliance (-35.9%, P = 0.002). No adverse effects were reported. Inhibitory tDCS improved the ABC rating scores for autistic behaviors. Owing to its ease of use, cost-effectiveness and the limited availability of specific treatment strategies, tDCS might be a valid therapeutic option to be tested in autistic patients. 10 daily applications of 20 min/1.5 mA/cathodal (inhibitory) tDCS over the left dorso-lateral pre-frontal cortex
Transcranial Direct Current Stimulation for Autistic Disorder Mr P manifested an overall substantial improvement in his abnormal behaviors, as evidenced by a 40.2% reduction in the total ABC score compared with the basal score. A direct

current of 1.5 mA was applied for 20 minutes every day.

To keep up to date on the latest studies, and clinical evidence for TENS PEMF therapy in the management of Autism Spectrum Disorder, please feel free to join our newsletter, or check back periodically.


  • -

TENS PEMF in the management of Anxiety and Generalized Anxiety Disorder

The following studies represent the clinical evidence for the use of TENS PEMF in the management of Anxiety and Generalized Anxiety Disorder. Please note these studies were not done on the Rife PEMF device, but do represent outputs available on our devices.

PEMF Therapy for Depression

Cranial electrotherapy stimulation (CES): a safe and effective low cost means of anxiety control in a dental practice A double-blind placebo-controlled study was performed on 33 randomly selected dental patients to evaluate whether cranial electrotherapy stimulation (CES) is a viable procedure for reducing anxiety during routine dental procedures. The active CES treatment group was significantly less anxious than the placebo group at the conclusion of various dental procedures.  
A pilot study of cranial electrotherapy stimulation for generalized anxiety disorder This preliminary study suggests that CES may reduce symptoms of anxiety in GAD. We hope that these preliminary results will encourage further research to explore the use of CES in clinical settings 0.5-Hz frequency and 300-muA intensity
Cranial electrotherapy stimulation as a treatment for anxiety in chemically dependent persons Cranial electrotherapy stimulation (CES) is reported to be an effective treatment for anxiety, a major presenting symptom among chemically dependent patients. In this study, 40 inpatient alcohol and/or polydrug users were given CES or sham CES in a double blind design. An additional 20 patients served as normal hospital routine controls. Dependent measures of anxiety were the Profile of Mood States, the Institute for Personality and Ability Testing Anxiety Scale, and the State/Trait Anxiety Index. CES-treated patients showed significantly greater improvement on all anxiety measures than did either control group. There were no differences in response between older and younger patients, or between the primarily drug or alcohol abusers. No placebo effect was found on any of our measures. It is concluded tht CES is a clinically significant addition to the treatment regimen for this patient population  
Cranial Electrotherapy Stimulation (CES) in the treatment of anxiety and other stress-related disorders: a review of controlled clinical trials A total of 34 controlled clinical trials concerning the efficacy of CES in the treatment of anxiety and other stress-related disorders were evaluated. Overall the results suggest that CES may be capable of producing significant (p < 0.05) benefit in the short-term symptomatic relief of anxiety and other stress-related disorders. CES may be effective alone and as an adjunct to other conservative measures of treatment. The primary mechanism of action of CES appears to be a direct effect on the brain followed by secondary responses  

To keep up to date on the latest studies, and clinical evidence for TENS PEMF in the management of Anxiety and Generalized Anxiety Disorder, please feel free to join our newsletter, or check back periodically.


  • -

TENS PEMF therapy in the management of Asthma and COPD

The following studies represent some of the clinical evidence for the use of TENS PEMF therapy in the management of Asthma and COPD.

Please note that these studies were not done on the Rife PEMF device, but rather represent studies including outputs which can be found on the various Rife Model MA devices.

 

Asthma and COPD

Randomized controlled trial of transcutaneous electrical muscle stimulation(TEMS) in patients with chronic COPD TEMS improved quadriceps strength (20% vs 8%), hamstring strength (13% vs 4.7%), and resulted in better performance in shuttle walk test (36% vs 1.6%) 50Hz – 20mins each limb, 3 days a week for 6 six weeks
Effects of PEMF on interleukin-1 beta and postoperative pain: a double-blind, placebo-controlled, pilot study in breast reduction patients. Mean IL-1 beta concentration in the wound exudates of treated patients was 275 percent lower (p < 0.001). Pulsed electromagnetic fields produced a 57 percent decrease in mean pain scores at 1 hour (p < 0.01) and a 300 percent decrease at 5 hours (p < 0.001), persisting to 48 hours postoperatively in the active versus the control group, along with a concomitant 2.2-fold reduction in narcotic use in active patients (p = 0.002). Unknown
Effect of TENS and AcuTens on Airway Obstructive Diseases Forced expiratory volume in treatment group increased by 13.1% and decreased in the sham group. Tens Group also increased performance in 6-minute walk test versus a decrease in the sham group. Significant increase in beta-endorphin levels in TENS group versus a decrease in the sham group. TENS has an immediate and cumulative effect on CPD and asthma. http://ira.lib.polyu.edu.hk/handle/10397/2703 2Hz Pulse
Effects of acupuncture-like transcutaneous electrical nerve stimulation on children with asthma The pediatric asthma quality-of-life questionnaire activities of the experimental group improved significantly more than those of the control group. Unknown
AcuTENS on post exercise lung volume in subjects with Asthma – Randomized controlled study Expiratory lung volume increased in treatment group versus decreasing in sham groups and this increase became more marked 20, 40 and 60 minutes after treatment 2Hz

For more information, research and studies on TENS PEMF therapy in the management of Asthma and COPD, please join our newsletter or check back regularly for updates.


  • -

TENS PEMF therapy in the management of ADD and ADHD

The following studies represent the clinical evidence for the use of TENS PEMF therapy in the management of ADD and ADHD. Please note these studies were not done on the Rife PEMF device, but do represent outputs available on our devices.

TENS PEMF therapy in the management of ADD and ADHD

For more information on ADHD and ADD, please read our article: TENS therapy for ADHD – ADHD Alternatives to medication

Effects of transcutaneous electrical nerve stimulation (TENS) on cognition, behavior, and the rest-activity rhythm in children with ADHD Twenty-two children diagnosed with ADHD-CT received TENS treatment during 6 weeks, 2 times 30 min a day. Neuropsychological tests were administered to assess cognition, parent/teacher behavioral rating scales were used to measure behavior, and actigraphy was used to assess the rest-activity rhythm. TENS appeared to have a moderate beneficial influence on cognitive functions that load particularly on executive function. There was also improvement in behavior as measured by parent/teacher behavioral rating scales. Moreover, motor restlessness during sleep and motor activity during the day decreased by TENS. CONCLUSIONS: The effects of TENS in children with ADHD are modest but encouraging and warrant further research.
Transcranial magnetic stimulation (TMS) in the treatment of attention-deficit/hyperactivity disorder in adolescents and young adults: a pilot study In 2012, Weaver et al. performed a pilot trial of 9 adolescents and young adults, age 15-20, using 10 Hz rTMS to the right dorsolateral prefrontal cortex 97. Subjects underwent 10 sessions over two weeks and each subject was crossed-over to receive sham. The objective of the study was to assess safety and the conclusion was that this was that rTMS was safe in this cohort, but the study was underpowered to show efficacy. Although the authors reported an improvement in core ADHD symptoms in the treatment group the effect did not differ significantly from the sham condition. 10Hz
Positive effects of repetitive transcranial magnetic stimulation on attention in ADHD Subjects: a randomized controlled pilot study. In 2010, Bloch et al. performed a double blind, randomized, sham controlled crossover pilot study with positive effects in 13 patients
Effectiveness of the repetitive Transcranical Magnetic Stimulation (rTMS) of 1 Hz for Attention-Deficit Hyperactivity Disorder (ADHD). The purpose of our study is to verify the therapeutic effectiveness of repetitive Transcranial Magnetic Stimulation (low frequency (1Hz, 1200 stim/die for five days)), applied on the impending scalp additional motor area, in a subject affected by ADHD. Results show a significant improvement that lasted for at least 4 weeks. Placebo control did not show any improvement. 1Hz
Saftey of TMS TMS has been used in over 800 normal children and over 300 neurologically abnormal children, with a good tolerability and safety profile 105,106. No change in auditory function has been reported in the pediatric population to date 105. Single- or paired-pulse TMS has not been shown to cause seizures in children, including those with epilepsy or with conditions like cerebral palsy that are associated with increased risk of seizures 101,107-113. One case of rTMS-induced seizure was reported in an adolescent patient being treated for depression 114, though other risk factors for seizure were also present, including alcohol use the night before the induced seizure 95. In 2009, a consensus conference issued recommendations for the safe use TMS in the pediatric population. They concluded that single-pulse and paired-pulse TMS was safe for children two years and older. In the absence of an appreciable volume of data on the potential for adverse effects with rTMS, they recommended that children should not be used as subjects for rTMS without compelling clinical reasons, such as the treatment of particular psychiatric conditions
Noninvasive Brain Stimulation in Pediatric ADHD: A Review An ongoing study is investigating the use of tDCS in adult patients with ADHD, which uses anodal tDCS stimulation over the left dorsolateral preftonal cortex at 1 mA127. The aim of this parallel, randomized, double-blind, sham-controlled trial is to study the modulation of inhibitory control in this population. While the results of tDCS in ADHD are not yet available there is a burgeoning literature suggesting that tDCS may be used to improve cognitive performance. These studies have shown that tDCS can improve behavioural inhibition, memory, and attention in healthy subjects 128,129, and these findings extend to clinical populations 127,130. There is reason to be optimistic that similar stimulation paradigms may have a beneficial effect for ADHD patients, though it will be critical that future studies be sufficiently powered and include a sham-controlled experimental design.
Transcranial direct current stimulation improves clinical symptoms in adolescents with attention deficit hyperactivity disorder Anodal transcranial direct current stimulation (tDCS) of the prefrontal cortex has repeatedly been shown to improve working memory. As patients with attention deficit hyperactivity disorder (ADHD) are characterized by both underactivation of the prefrontal cortex and deficits in working memory that correlate with clinical symptoms, it is hypothesized that the modulation of prefrontal activity with tDCS in patients with ADHD increases performance in working memory and reduces symptoms of ADHD. To test this hypothesis, fifteen adolescents with ADHD (12-16 years old, three girls and 12 boys) were treated according to the randomized, double-blinded, sham-controlled, crossover design with either 1 mA anodal tDCS over the left dorsolateral prefrontal cortex or with the sham protocol 5 days each with a 2 weeks pause between these conditions. Anodal tDCS caused a significant reduction in clinical symptoms of inattention and impulsivity in adolescents with ADHD compared to sham stimulation. The clinical effects were supported by a significant reduction in inattention and hyperactivity in a standardized working memory test (QbTest). The described effects were more pronounced 7 days after the end of stimulation, a fact which emphasizes the long-lasting clinical and neuropsychological changes after tDCS. This study provides the first evidence that tDCS may reduce symptoms of ADHD and improve neuropsychological functioning in adolescents and points on the potential of tDCS as a form of treatment for ADHD. 1 mA
Positive effects of transcranial direct current stimulation in adult patients with attention-deficit/hyperactivity disorder - A pilot randomized controlled study. We performed a double-blind, sham-controlled randomized clinical trial in 17 patients with ADHD. The set up for tDCS was the following: 2mA/20min/day for 5 days with the anode over the right dorsolateral prefrontal cortex and cathode over the left dorsolateral prefrontal cortex. ADHD symptoms were measured by the Adult ADHD Self-Report Scale (ASRS) and impairment with the Sheehan Disability Scale (SDS) in four different time points after stimulation. Participants achieved significant lower ASRS inattention and SDS scores after active tDCS in comparison with sham stimulation group. In addition, we detected a trend for a lower ASRS total score in the active tDCS group. Follow up data analysis revealed a positive interaction between time and treatment in both ASRS inattention, SDS and ASRS total scores. Short-term application of tDCS in adult patients with ADHD improved their symptoms, and this improvement persisted after the end of the stimulation. Future studies with larger sample sizes are needed. 2mA/20min/day

To keep up to date on the latest studies, and clinical evidence for TENS PEMF therapy in the management of ADD and ADHD, please feel free to join our newsletter, or check back periodically.


  • -

Rife PEMF Patch Coils

Rife PEMF Patch Coils

The PEMF Patches allow you to take advantage of using patches which provide an effective way of supplying the TENS effect of the device in conjunction with our PEMF coil technology. Patches can be used for about 20 applications before they will need to be replaced. The patches allow you to place the coils as close to the area of application as possible. The elastics supplied with the coils allow you to secure the coils if necessary.

To purchase your Patch coils, click here.

In your patch coils you will receive:

2 large orange disks. These are the coils
2 small white adhesive patches. These are the electrode patches
2 pairs of elastics. These allow you to tie the patch coils to the area you want to treat

Wipe coils areas with a damp cloth to clean if needed. Patches are designed to last for between 10 and 20 therapy sessions. New patches can be purchased from our website or you can email us at info@rifepemf.com  

 Rife PEMF Self-Adhesive Electrodes

The self-adhesive electrodes are intended for use with the Rife PEMF device. To purchase replacement electrodes, click here.


  • -

PEMF TENS Alzheimer Update: The Alzheimer HSV1 link

It was recently brought to our attention that in many cases, the Herpes Simplex Virus 1 could play a role in Alzheimer disease which is why we are writing the PEMF TENS Alzheimer Update. According to an article in Medical News Today, there are numerous studies which now site links between the Herpes Virus and previous Herpes infections and the development and progression of Alzheimer disease.

According to studies the Herpes Virus can harm brain cells and the accumulation of damage can contribute to the development and progression of the condition.

An article in ScienceDaily outlines how scientists at the University of Edinburgh and Manchester discovered through an epidemiological study that the use of antivirals can reduce the risk of developing dementia or Alzheimer’s disease.

PEMF TENS Alzheimer

The Herpes Simplex Virus is most often associated with cold sores and antiherpetic medication could therefore potentially be used to reduce the risk of both Alzheimer’s disease and dementia.

PEMF therapy helps to support Alzheimer and Dementia patients by improving various symptoms within the disease by improving circulation, reducing inflammation and address pain and discomfort. For more information on how PEMF therapy benefits Alzheimer disease, please read our article. Studies also indicate that PEMF and TENS therapy can have beneficial outcomes for the nervous system and that PEMF and TENS therapy is generally considered safe, which makes PEMF TENS therapy a good choice for adjuvant therapy for Alzheimer patients.

PEMF TENS Alzheimer Update: The rife protocol for Alzheimer Disease

As a result of the above studies and many other PEMF TENS studies on Alzheimer disease, we have amended our Alzheimer protocol to include programs to address some of the Herpes Viruses mentioned in the above studies. For the herpes therapy, please use the Patch coils to ensure an effective whole body therapy.

The current protocol includes the program for the herpes virus available on the MA700 and some available on the MA200. To reprogram or upgrade your MA200, please feel free to email us.

 


Cart